The Food and Drug Administration on Wednesday gave expanded approval to OraSure Technologies' OraQuick rapid HIV test for use in hospitals to screen blood drawn intravenously for HIV antibodies. The rapid HIV test can produce results in about 20 minutes. The test was previously approved only to test blood obtained from finger pricks, making it an ideal screening method for HIV/AIDS organizations offering HIV testing services. OraSure president of marketing William Bruckner said the expanded approval means that the test can now be used on the roughly 12 million people screened for HIV infection at U.S. hospitals each year. The company is currently completing clinical trials evaluating the effectiveness of OraQuick in detecting HIV antibodies in oral fluids and trials to determine whether the test can detect antibodies in the blood to HIV-2, a less common strain of the virus prevalent in West Africa.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved














